FDA updates draft guidance to set a clear path for the nonproprietary naming of interchangeable biosimilars.
Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s steps on naming of biological medicines to balance competition and safety for patients receiving these products
More from FDA News AlertsMore posts in FDA News Alerts »
- FDA Allows for First Point-of-Care Chlamydia and Gonorrhea Test to be Used in More Near-Patient Care Settings
- Coronavirus (COVID-19) Update: March 30, 2021
- Bit & Bet LLC Issues Voluntary Nationwide Recall of Thumbs Up 7 Blue 69K Due to Presence of Undeclared Sildenafil and Tadalafil
- Mammography Problems at Tennessee Women’s Care P.C. in Nashville, TN: FDA Safety Communication